Corrigendum: Blood-Based DNA Methylation Biomarkers for Type 2 Diabetes: Potential for Clinical Applications

Tarryn Willmer¹, Rabia Johnson^{1

2}, Johan Louw^{1

3}, Carmen Pheiffer^{1

2}

Affiliations

¹ Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South Africa.
² Division of Medical Physiology, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa.
³ Department of Biochemistry and Microbiology, University of Zululand, Kwa-Dlangezwa, South Africa.

Published Erratum

Tarryn Willmer et al. Front Endocrinol (Lausanne). 2019.

. 2019 Jan 22:10:1.

doi: 10.3389/fendo.2019.00001. eCollection 2019.

Tarryn Willmer¹, Rabia Johnson^{1

2}, Johan Louw^{1

3}, Carmen Pheiffer^{1

2}

¹ Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South Africa.
² Division of Medical Physiology, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa.
³ Department of Biochemistry and Microbiology, University of Zululand, Kwa-Dlangezwa, South Africa.

Abstract

[This corrects the article DOI: 10.3389/fendo.2018.00744.].

Keywords: biomarkers; blood; gene-specific DNA methylation; genome-wide DNA methylation; global DNA methylation; type 2 diabetes.

Blood-Based DNA Methylation Biomarkers for Type 2 Diabetes: Potential for Clinical Applications.
Willmer T, Johnson R, Louw J, Pheiffer C. Willmer T, et al. Front Endocrinol (Lausanne). 2018 Dec 4;9:744. doi: 10.3389/fendo.2018.00744. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30564199 Free PMC article. Review.